AU2019225166B2 - Small molecules for inducing selective protein degradation and uses thereof - Google Patents
Small molecules for inducing selective protein degradation and uses thereof Download PDFInfo
- Publication number
- AU2019225166B2 AU2019225166B2 AU2019225166A AU2019225166A AU2019225166B2 AU 2019225166 B2 AU2019225166 B2 AU 2019225166B2 AU 2019225166 A AU2019225166 A AU 2019225166A AU 2019225166 A AU2019225166 A AU 2019225166A AU 2019225166 B2 AU2019225166 B2 AU 2019225166B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- certain embodiments
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634679P | 2018-02-23 | 2018-02-23 | |
| US62/634,679 | 2018-02-23 | ||
| PCT/US2019/019180 WO2019165229A1 (en) | 2018-02-23 | 2019-02-22 | Small molecules for inducing selective protein degradation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019225166A1 AU2019225166A1 (en) | 2020-08-06 |
| AU2019225166B2 true AU2019225166B2 (en) | 2024-10-31 |
Family
ID=67687887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019225166A Active AU2019225166B2 (en) | 2018-02-23 | 2019-02-22 | Small molecules for inducing selective protein degradation and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11802132B2 (https=) |
| EP (1) | EP3755325A4 (https=) |
| JP (2) | JP7472026B2 (https=) |
| CN (1) | CN112020358A (https=) |
| AU (1) | AU2019225166B2 (https=) |
| CA (1) | CA3090417A1 (https=) |
| WO (1) | WO2019165229A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| US10254389B2 (en) | 2015-11-06 | 2019-04-09 | Artilux Corporation | High-speed light sensing apparatus |
| US10886309B2 (en) | 2015-11-06 | 2021-01-05 | Artilux, Inc. | High-speed light sensing apparatus II |
| US10418407B2 (en) | 2015-11-06 | 2019-09-17 | Artilux, Inc. | High-speed light sensing apparatus III |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11105928B2 (en) | 2018-02-23 | 2021-08-31 | Artilux, Inc. | Light-sensing apparatus and light-sensing method thereof |
| US11482553B2 (en) | 2018-02-23 | 2022-10-25 | Artilux, Inc. | Photo-detecting apparatus with subpixels |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| US10886311B2 (en) | 2018-04-08 | 2021-01-05 | Artilux, Inc. | Photo-detecting apparatus |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3807272A1 (en) | 2018-06-13 | 2021-04-21 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2022006861A (es) | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| KR20230005160A (ko) | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| JP2024513566A (ja) * | 2021-04-09 | 2024-03-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的基質の選択的修飾のための二官能性分子 |
| US20240245787A1 (en) | 2021-04-13 | 2024-07-25 | President And Fellows Of Harvard College | E3 ligase binders and uses thereof |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
| WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106725A1 (en) * | 2013-05-08 | 2016-04-21 | The Johns Hopkins University | Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity |
| US20160176916A1 (en) * | 2014-12-23 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053245A1 (en) | 2007-05-29 | 2009-02-26 | Mutz Mitchell W | Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood |
| EP2667196A1 (en) | 2012-05-26 | 2013-11-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bioorthogonal chemical inducers of reversible dimerization for control of protein interactions in cells |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
-
2019
- 2019-02-22 CA CA3090417A patent/CA3090417A1/en active Pending
- 2019-02-22 CN CN201980027535.9A patent/CN112020358A/zh active Pending
- 2019-02-22 AU AU2019225166A patent/AU2019225166B2/en active Active
- 2019-02-22 US US16/969,772 patent/US11802132B2/en active Active
- 2019-02-22 EP EP19757828.9A patent/EP3755325A4/en active Pending
- 2019-02-22 JP JP2020544488A patent/JP7472026B2/ja active Active
- 2019-02-22 WO PCT/US2019/019180 patent/WO2019165229A1/en not_active Ceased
-
2024
- 2024-02-06 JP JP2024016079A patent/JP7820423B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106725A1 (en) * | 2013-05-08 | 2016-04-21 | The Johns Hopkins University | Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity |
| US20160176916A1 (en) * | 2014-12-23 | 2016-06-23 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3755325A4 (en) | 2022-03-02 |
| JP7820423B2 (ja) | 2026-02-25 |
| US11802132B2 (en) | 2023-10-31 |
| CA3090417A1 (en) | 2019-08-29 |
| AU2019225166A1 (en) | 2020-08-06 |
| JP2021514958A (ja) | 2021-06-17 |
| JP2024054209A (ja) | 2024-04-16 |
| CN112020358A (zh) | 2020-12-01 |
| WO2019165229A1 (en) | 2019-08-29 |
| JP7472026B2 (ja) | 2024-04-22 |
| EP3755325A1 (en) | 2020-12-30 |
| US20200407371A1 (en) | 2020-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019225166B2 (en) | Small molecules for inducing selective protein degradation and uses thereof | |
| AU2017363313B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
| AU2017252460B2 (en) | EZH2 inhibitors and uses thereof | |
| US12187701B2 (en) | Taire family kinase inhibitors and uses thereof | |
| AU2020294169B2 (en) | Acetamide thienotriazolodiazepines and uses thereof | |
| JP7660063B2 (ja) | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 | |
| AU2019224089B2 (en) | Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof | |
| JP7680999B2 (ja) | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 | |
| CA2996974A1 (en) | Cyano thienotriazolodiazepines and uses thereof | |
| US20230117680A1 (en) | Cyclophilin d inhibitors and uses thereof | |
| US20250109165A1 (en) | Cyclophilin inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |